Recursion Pharmaceuticals (RXRX) Competitors $5.41 -0.07 (-1.28%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$5.46 +0.05 (+1.02%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX vs. BBIO, VRNA, BPMC, ROIV, GRFS, LEGN, ELAN, RVMD, RGC, and RYTMShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Regencell Bioscience (RGC), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Regencell Bioscience Rhythm Pharmaceuticals BridgeBio Pharma (NASDAQ:BBIO) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Which has stronger earnings and valuation, BBIO or RXRX? Recursion Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M39.59-$535.76M-$4.09-11.23Recursion Pharmaceuticals$64.51M34.09-$463.66M-$1.78-3.04 Is BBIO or RXRX more profitable? BridgeBio Pharma has a net margin of -329.25% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. BridgeBio Pharma's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% Recursion Pharmaceuticals -1,004.91%-76.09%-54.29% Which has more risk and volatility, BBIO or RXRX? BridgeBio Pharma has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Do analysts prefer BBIO or RXRX? BridgeBio Pharma currently has a consensus price target of $61.35, indicating a potential upside of 33.52%. Recursion Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 29.39%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor BBIO or RXRX? In the previous week, BridgeBio Pharma had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 21 mentions for BridgeBio Pharma and 14 mentions for Recursion Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.34 beat Recursion Pharmaceuticals' score of -0.09 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders & institutionals believe in BBIO or RXRX? 99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryBridgeBio Pharma beats Recursion Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.23B$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.18%P/E Ratio-3.0419.6629.8725.14Price / Sales34.09634.80422.9397.17Price / CashN/A165.0335.9458.58Price / Book2.394.198.105.59Net Income-$463.66M$31.61M$3.26B$265.48M7 Day Performance-4.75%0.95%0.64%1.22%1 Month Performance0.93%2.90%2.42%0.39%1 Year Performance-18.52%4.11%27.60%23.47% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals1.877 of 5 stars$5.41-1.3%$7.00+29.4%-15.1%$2.23B$64.51M-3.04400Earnings ReportBBIOBridgeBio Pharma4.7197 of 5 stars$47.74+0.8%$61.18+28.1%+92.1%$9.06B$127.42M-13.52400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeVRNAVerona Pharma PLC American Depositary Share1.8744 of 5 stars$105.34+0.1%$109.00+3.5%+439.7%$8.54B$118.54M-52.6530Trending NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.6943 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.361 of 5 stars$11.43+1.0%$16.50+44.4%+13.6%$7.77B$29.05M-45.74860Positive NewsUpcoming EarningsGRFSGrifols3.2055 of 5 stars$10.73-0.5%$10.30-4.0%+43.3%$7.38B$7.81B9.1823,822Analyst ForecastLEGNLegend Biotech3.8424 of 5 stars$38.67-0.3%$73.33+89.6%-32.0%$7.12B$728.30M-65.642,609News CoveragePositive NewsUpcoming EarningsAnalyst RevisionELANElanco Animal Health3.3469 of 5 stars$14.12+2.4%$16.17+14.5%+32.4%$7.02B$4.43B19.099,000Trending NewsEarnings ReportGap UpRVMDRevolution Medicines4.45 of 5 stars$36.73+0.3%$68.91+87.6%-17.3%$6.85BN/A-9.20250News CoverageEarnings ReportAnalyst ForecastGap DownRGCRegencell Bioscience0.1556 of 5 stars$13.39+3.2%N/AN/A$6.62BN/A0.0010Positive NewsRYTMRhythm Pharmaceuticals3.5698 of 5 stars$89.30+1.1%$91.93+2.9%+112.3%$5.68B$136.86M-31.80140Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Grifols Competitors Legend Biotech Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Regencell Bioscience Competitors Rhythm Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
